Oleic acid activates peroxisome proliferator-activated receptor δ to compensate insulin resistance in steatotic cells

Journal of Nutritional Biochemistry

Volumn 23, Issue 10, 2012, Pages 1264-1270

  Wu, Hung Tsung ^a   Chen, Wency ^b   Cheng, Kai Chun ^c   Ku, Po Ming ^d   Yeh, Ching Hua ^e   Cheng, Juei Tang ^a,d,e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

Hepatic steatosis; Insulin resistance; Oleic acid; Peroxisome proliferator activated receptor ; PTEN

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; G PROTEIN COUPLED RECEPTOR 40; INSULIN; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE C; SMALL INTERFERING RNA;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME INHIBITION; GENE DELETION; GENETIC TRANSFECTION; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL; NONALCOHOLIC FATTY LIVER; PROTEIN EXPRESSION;

ANIMALS; HEP G2 CELLS; HEPATOCYTES; HUMANS; INSULIN RESISTANCE; MICE; OLEIC ACID; PPAR DELTA; PTEN PHOSPHOHYDROLASE; RECEPTORS, G-PROTEIN-COUPLED; TYPE C PHOSPHOLIPASES;

EID: 84866316797     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.07.006     Document Type: Article

References (51)

1. Contos MJ, Choudhury J, Mills AS, Sanyal AJ. The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:481-500, vii.
2. Adams L.A., Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005, 22:1129-1133.
3. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
4. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-455.
5. Samuel V.T., Liu Z.X., Qu X., Elder B.D., Bilz S., Befroy D., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279:32345-32353.
6. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
7. Falchuk K.R., Fiske S.C., Haggitt R.C., Federman M., Trey C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology 1980, 78:535-541.
8. Stone B.G., Van Thiel D.H. Diabetes mellitus and the liver. Semin Liver Dis 1985, 5:8-28.
9. James O.F., Day C.P. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998, 29:495-501.
10. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
11. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
12. Rinella M.E., Green R.M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004, 40:47-51.
13. Prentki M., Madiraju S.R. Glycerolipid metabolism and signaling in health and disease. Endocr Rev 2008, 29:647-676.
14. Nolan C.J., Larter C.Z. Lipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it?. J Gastroenterol Hepatol 2009, 24:703-706.
15. Ricchi M., Odoardi M.R., Carulli L., Anzivino C., Ballestri S., Pinetti A., et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009, 24:830-840.
16. De Gottardi A., Vinciguerra M., Sgroi A., Moukil M., Ravier-Dall'Antonia F., Pazienza V., et al. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest 2007, 87:792-806.
17. Schulman I.G. Nuclear receptors as drug targets for metabolic disease. Adv Drug Deliv Rev 2010, 62:1307-1315.
18. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
19. Beaven S.W., Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 2006, 57:313-329.
20. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
21. Reddy J.K. Nonalcoholic steatosis and steatohepatitis: III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1333-G1339.
22. Kallwitz E.R., McLachlan A., Cotler S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008, 14:22-28.
23. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004, 10:1245-1250.
24. Labonte E.D., Pfluger P.T., Cash J.G., Kuhel D.G., Roja J.C., Magness D.P., et al. Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity. FASEB J 2010, 24:2516-2524.
25. Qin X., Xie X., Fan Y., Tian J., Guan Y., Wang X., et al. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology 2008, 48:432-441.
26. Suh H.N., Huong H.T., Song C.H., Lee J.H., Han H.J. Linoleic acid stimulates gluconeogenesis via Ca2+/PLC, cPLA2, and PPAR pathways through GPR40 in primary cultured chicken hepatocytes. Am J Physiol Cell Physiol 2008, 295:C1518-C1527.
27. Cui W., Chen S.L., Hu K.Q. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2010, 2:95-104.
28. Edvardsson U., Ljungberg A., Oscarsson J. Insulin and oleic acid increase PPARgamma2 expression in cultured mouse hepatocytes. Biochem Biophys Res Commun 2006, 340:111-117.
29. Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010, 5:145-171.
30. Araya J., Rodrigo R., Videla L.A., Thielemann L., Orellana M., Pettinelli P., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
31. Wang S.R., Pessah M., Infante J., Catala D., Salvat C., Infante R. Lipid and lipoprotein metabolism in Hep G2 cells. Biochim Biophys Acta 1988, 961:351-363.
32. Okamoto Y., Tanaka S., Haga Y. Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model. Hepatol Res 2002, 23:138-144.
33. Janorkar A.V., King K.R., Megeed Z., Yarmush M.L. Development of an in vitro cell culture model of hepatic steatosis using hepatocyte-derived reporter cells. Biotechnol Bioeng 2009, 102:1466-1474.
34. Farkas M.H., Swift L.L., Hasty A.H., Linton M.F., Fazio S. The recycling of apolipoprotein E in primary cultures of mouse hepatocytes. Evidence for a physiologic connection to high density lipoprotein metabolism. J Biol Chem 2003, 278:9412-9417.
35. Spector A.A. Fatty acid binding to plasma albumin. J Lipid Res 1975, 16:165-179.
36. Chen Z.C., Yu B.C., Chen L.J., Cheng K.C., Lin H.J., Cheng J.T. Characterization of the mechanisms of the increase in PPARdelta expression induced by digoxin in the heart using the H9c2 cell line. Br J Pharmacol 2011, 163:390-398.
37. Hsu J.H., Liou S.S., Yu B.C., Cheng J.T., Wu Y.C. Activation of alpha1A-adrenoceptor by andrographolide to increase glucose uptake in cultured myoblast C2C12 cells. Planta Med 2004, 70:1230-1233.
38. Guidorizzi de Siqueira A.C., Cotrim H.P., Rocha R., Carvalho F.M., de Freitas L.A., Barreto D., et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 2005, 17:837-841.
39. Lonardo A., Lombardini S., Scaglioni F., Carulli L., Ricchi M., Ganazzi D., et al. Hepatic steatosis and insulin resistance: does etiology make a difference?. J Hepatol 2006, 44:190-196.
40. Matsumoto M., Han S., Kitamura T., Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 2006, 116:2464-2472.
41. Liu S., Hatano B., Zhao M., Yen C.C., Kang K., Reilly S.M., et al. Role of peroxisome proliferator-activated receptor delta/beta in hepatic metabolic regulation. J Biol Chem 2011, 286:1237-1247.
42. Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176.
43. Briscoe C.P., Tadayyon M., Andrews J.L., Benson W.G., Chambers J.K., Eilert M.M., et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003, 278:11303-11311.
44. Long Y.C., Glund S., Garcia-Roves P.M., Zierath J.R. Calcineurin regulates skeletal muscle metabolism via coordinated changes in gene expression. J Biol Chem 2007, 282:1607-1614.
45. Lunde I.G., Ekmark M., Rana Z.A., Buonanno A., Gundersen K. PPARdelta expression is influenced by muscle activity and induces slow muscle properties in adult rat muscles after somatic gene transfer. J Physiol 2007, 582:1277-1287.
46. Arendt B.M., Mohammed S.S., Aghdassi E., Prayitno N.R., Ma D.W., Nguyen A., et al. Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J Nutr 2009, 139:691-695.
47. Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010;138:932-41 e1-3.
48. Pang M., de la Monte S.M., Longato L., Tong M., He J., Chaudhry R., et al. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 2009, 50:1192-1201.
49. Peyrou M., Bourgoin L., Foti M. PTEN in liver diseases and cancer. World J Gastroenterol 2010, 16:4627-4633.
50. Vinciguerra M., Sgroi A., Veyrat-Durebex C., Rubbia-Brandt L., Buhler L.H., Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009, 49:1176-1184.
51. Han S., Ritzenthaler J.D., Zheng Y., Roman J. PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1238-L1249.